The Italy TFR registry collects data on patients with Philadelphia chromosome-positive (Ph+), chronic phase chronic myeloid leukemia (CML) who discontinue tyrosine kinase inhibitor (TKI) therapy and enter a period of treatment-free remission (TFR). Elisabetta Abruzzese, MD, PhD, S. Eugenio University Hospital, Rome, Italy, discusses the findings of a sub-analysis of pregnant patients included in this registry, which aimed to understand the outcomes in this patient group. This group varied in age and rates of major molecular remission (MMR) compared to those patients in the registry who were not pregnant. All pregnant patients were drug-free at the time of organogenesis, and all pregnancies were uneventful. After the placenta had formed, patients could resume treatment with imatinib or nilotinib. Enrollment is ongoing for a prospective cohort in the Italy TFR registry, but current data suggest that entering TFR is feasible in both planned and unplanned pregnancies as long as an interdisciplinary team is available to manage those patients who would not otherwise reach the criteria for entering TFR. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
